oragallin purum tablet
takeda austria gmbh - azintamide - tablet - 100 mg
ubretid tablet
takeda austria gmbh - distigmine bromide - tablet - 5 mg
ubretid 0.5mg amp injection
takeda austria gmbh - distigmine bromide - injection - 0.5 mg
actovegin solution for injection
takeda austria gmbh - deproteinised haemoderivate of calf blood - solution for injection - 40mg/ml
xefocam powder lyophilized for solution for i/v and i/m injection
takeda austria gmbh - lornoxicam - powder lyophilized for solution for i/v and i/m injection - 8mg
xefocam powder lyophilized for solution for i/v and i/m injection
takeda austria gmbh - lornoxicam - powder lyophilized for solution for i/v and i/m injection - 8mg
xefo 8 mg film-coated tablets 8 milligram film coated tablet
takeda uk limited - lornoxicam - film coated tablet - 8 milligram
ninlaro ixazomib (as citrate) 2.3mg capsule blister pack
takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 3.29 mg (equivalent: ixazomib, qty 2.3 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
ninlaro ixazomib (as citrate) 3mg capsule blister pack
takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 4.3 mg (equivalent: ixazomib, qty 3 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide black; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
ninlaro ixazomib (as citrate) 4mg capsule blister pack
takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 5.7 mg (equivalent: ixazomib, qty 4 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.